Comorbidities in end-stage lung disease

Journal of Heart and Lung Transplantation

Volumn 18, Issue 9, 1999, Pages 891-903

  Minai, Omar A ^a   Maurer, Janet R ^a   Kesten, Steven ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PROSTACYCLIN;

BLOOD TOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COMPLICATION; COR PULMONALE; CORONARY ARTERY DISEASE; HEART LEFT VENTRICLE FAILURE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG CARCINOMA; LUNG DISEASE; LUNG EMBOLISM; LUNG TOXICITY; NEPHROTOXICITY; OSTEOPOROSIS; PNEUMOTHORAX; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR;

EID: 0032872479     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(99)00053-4     Document Type: Article

References (152)

1. Kanner R.E., Renzetti A.D. Jr, Stanish W.M., et al. Predictors of survival in subjects with chronic airflow limitation. Am J Med. 74:1983;249-255.
2. Charlson M., Szatrowski T.P., Peterson J., Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 47:1994;1245-1251.
3. Incalzi R.A., Fuso L., De Rosa M., et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 10:1997;2794-2800.
4. Panos R.J., Mortenson R.L., Niccoli S.A., King T.E. Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis causes and assessment . Am J Med. 88:1990;396-404.
5. Niederman M.S., Bass J.B., Campbell G.D., et al. Guidelines for the initial empiric therapy of community acquired pneumonia proceedings of an American Thoracic Society Consensus Conference . Am Rev Respir Dis. 148:1993;1418-1426.
6. Torres A., Serra-Batlles J., Ferrer A., et al. Severe community-acquired pneumonia epidemiology and prognostic factors . Am Rev Respir Dis. 144:1991;312-318.
7. Gilbert K., Fine M.J. Assessing prognosis and predicting patient outcomes in community acquired pneumonia. Semin Respir Infect. 9:1994;140-152.
8. Giron J.M., Poey C.G., Fajadet P.P., et al. Inoperable pulmonary aspergilloma percutaneous CT guided injection with glycerin and amphotericin B paste in 15 cases . Radiology. 188:1993;825-827.
9. Laufer P., Fink J.N., Bruns W.T., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. J Allergy Clin Immunol. 73:1984;44-48.
10. Shachor Y., Schindler D., Siegal A., et al. Increased incidence of pulmonary tuberculosis in chronic interstitial lung disease. Thorax. 44:1989;151-153.
11. Snider D.E. The relationship between tuberculosis and silicosis. Am Rev Respir Dis. 118:1978;455-460.
12. Al Jarad N., Demertzis P., Jones D.J., et al. Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis. Thorax. 51:1996;137-139.
13. Mera S.L. Senescence and pathology in ageing. Med Lab Sci. 49:1992;271-282.
14. U.S. Department of Health and Human Services. The health consequences of smoking. A report of the Surgeon General. DHHS Publication (PHS) 1984;84-50,205.
15. Turner-Warwick M., Lebowitz M., Burrows B., Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax. 35:1980;496-499.
16. Minai O.A., Dweik R.A., Arroliga A.C. Manifestations of scleroderma pulmonary disease. Clin Chest Med. 19:1998;713-731.
17. Finkelstein M.M. Mortality among employees of an Ontario asbestos cement factory. Am Rev Respir Dis. 129:1984;754-761.
18. DeLisser H.M., Grippi M.A. Perioperative respiratory considerations in the surgical patient. Fishman A.P., Elias J.A., Fishman J.A., Grippi M.A., Kaiser L.R., Senior R.M. Fishman's pulmonary diseases and disorders. 3rd ed. 1998;619-629 McGraw-Hill, New York.
19. Simonelli P.F., Thomashow B., Yip C., et al. Lung volume reduction and solitary pulmonary nodule resectional surgery in patients with advanced emphysema positron emission tomography may improve patient selection . Am J Respir Crit Care Med. 155:1997;A606.
20. Sause W.T., Machtay M. Treatment of non-small cell lung cancer radiation therapy . Fishman A.P., Elias J.A., Fishman J.A., Grippi M.A., Kaiser L.R., Senior R.M. Fishman's pulmonary diseases and disorders. 3rd ed. 1998;1805-1818 McGraw-Hill, New York.
21. Primary prevention of pulmonary heart disease. Circulation. 41:1970;A17-A23.
22. Matthay R.A., Berger H.J. Cardiovascular function in cor pulmonale. Clin Chest Med. 4:1983;269-295.
23. Harris P., Heath D. The human pulmonary circulation. 1977;353 Churchill Livingstone, New York.
24. Scharf S.M., Caldini P., Ingram R.H. Jr. Cardiovascular effects of increasing airway pressure in the dog. Am J Physiol. 232:1977;H43.
25. Bishop J.M. Cardiovascular complications of chronic bronchitis and emphysema. Med Clin North Am. 57:1973;771-780.
26. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med. 93:1980;391-398.
27. Long-term domociliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. i:1981;681-686.
28. Channick R.N., Newhart J.W., Johnson F.W., et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension an ambulatory delivery system and initial clinical tests . Chest. 109:1996;1545-1549.
29. Adnot S., Raffestin B. Pulmonary hypertension NO therapy? Thorax. 51:1996;762-764.
30. Rubin L.J. Primary pulmonary hypertension. Chest. 104:1993;236-250.
31. Olivari M.T. Primary pulmonary hypertension. Am J Med Sci. 302:1991;185-198.
32. Rubin L.J. Primary pulmonary hypertension. N Engl J Med. 336:1997;111-117.
33. Barst R.J., Rubin L.J., McGoon M.D., et al. Survival in primary pulmonary hypertension with long term continuous intravenous prostacyclin. Ann Intern Med. 121:1994;409-415.
34. Fedullo P.F., Auger W.R., Channick R.N., et al. Chronic thromboembolic pulmonary hypertension. Clin Chest Med. 16:1995;353-374.
35. Chitwood W.R., Sabiston D.C., Wechsler A.S. Surgical treatment of unresolved pulmonary embolism. Clin Chest Med. 5:1984;507-536.
36. Dines D.E., Clagett O.T., Payne W.S. Spontaneous pneumothorax in emphysema. Mayo Clinic Proc. 45:1970;481-487.
37. Light R.W., O'Hara V.S., Moritz T.E., et al. Intrapleural tetracycline for the prevention of recurrent spontaneous pneumothorax. JAMA. 264:1990;2224-2230.
38. Shields T.W., Oilschlager G.A. Spontaneous pneumothorax in patients 40 years of age and older. Ann Thorac Surg. 2:1966;377-383.
39. Picado C., de Almeida R.G., Xaubet A., et al. Spontaneous pneumothorax in cryptogenic fibrosing alveolitis. Respiration. 48:1985;77-80.
40. McLaughlin F.J., Matthews W.J. Jr, Streider D.J., et al. Pneumothorax in cystic fibrosis management and outcome . J Pediatr. 100:1982;863-869.
41. Luck S.R., Raffensperger J.G., Sullivan H.J., Gibson L.E. Management of pneumothorax in children with chronic pulmonary disease. J Thorac Cardiovasc Surg. 74:1977;834-839.
42. Dines D.E., Clagett O.T., Payne W.S. Spontaneous pneumothorax in emphysema. Mayo Clin Proc. 45:1970;481-487.
43. Boat T.F., Di SantAgnese P.A., Warwick W.J., Handwerger S.A. Pneumothorax in cystic fibrosis. JAMA. 209:1969;1498-1504.
44. Dusmet M., Winton T.L., Kesten S., Maurer J. Previous intrapleural procedures do not adversely affect lung transplantation. J Heart Lung Transplant. 15:1996;249-254.
45. Detterbeck F.C., Egan T.M., Mill M.R. Lung transplantation after previous thoracic surgical procedures. Ann Thorac Surg. 60:1995;139-143.
46. Moser K.M. Venous thromboembolism state of the art . Am Rev Respir Dis. 141:1990;235-249.
47. Carson J.L., Terrin M.L., Duffy A., Kelley M.A. Pulmonary embolism and mortality in patients with COPD. Chest. 110:1996;1212-1219.
48. Value of the ventilation/perfusion scan in acute pulmonary embolism results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) . JAMA. 263:1990;2753-2759.
49. Greenspan R.H. Pulmonary angiography and the diagnosis of pulmonary embolism. Prog Cardiovasc Dis. 37:1994;93-105.
50. Gefter W.B., Hatabu H., Holland G.A., et al. Pulmonary thromboembolism recent developments in diagnosis with CT and MRI imaging . Radiology. 197:1995;561-574.
51. Hommes D.W., Bura A., Mazzolai L., et al. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep venous thrombosis a meta-analysis . Ann Intern Med. 116:1992;279-284.
52. Kuller L.H., Ockene J.K., Townsend M., Browner W., Meilahn E., Wentworth D.N. The epidemiology of pulmonary function and COPD mortality in the multiple risk factor intervention trial. Am Rev Respir Dis. 140:1989;S76-S81.
53. Behar S., Panosh A., Reicher-Reiss H., et al. Prevalence and prognosis of chronic obstructive pulmonary disease among 5,839 consecutive patients with acute myocardial infarction. SPRINT Study Group. Am J Med. 93:1992;637-641.
54. Wahl G.W., Swinburne A.J., Fedullo A.J., et al. Effect of age and preoperative airway obstruction on lung function after coronary artery bypass grafting. Ann Thorac Surg. 56:1993;104-107.
55. Samuels L.E., Kaufman M.S., Morris R.J., et al. Coronary artery bypass grafting in patients with COPD. Chest. 113:1998;878-882.
56. Cohen A., Katz M., Katz R., et al. Chronic obstructive pulmonary disease in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 109:1995;574-581.
57. Borley N.R., Large S.R. An unusual opportunity to reduce operative risk by combining cardiac and pulmonary procedures. Eur J Cardiothorac Surg. 9:1995;40-41.
58. Johnson J.A., Landreneau R.J., Boley T.M., et al. Should pulmonary lesions be resected at the time of open heart surgery? Am Surg. 62:1996;300-303.
59. Rao V., Todd T.R., Weisel R.D., et al. Results of combined pulmonary resection and cardiac operation. Ann Thorac Surg. 62:1996;342-346.
60. Danton M.H., Anikin V.A., McManus K.G., et al. Simultaneous cardiac surgery with pulmonary resection presentation of series and review of literature . Eur J Cardiothorac Surg. 13:1998;667-672.
61. Voets A.J., Joesoef K.S., van Teeffelen M.E. Synchroneously occurring lung cancer (stages I-II) and coronary artery disease concomitant versus staged surgical approach . Eur J Cardiothorac Surg. 12:1997;713-717.
62. Liopyris P., Triantafillou A.N., Sundt T.M. III, et al. Coronary artery bypass grafting after a bilateral lung volume reduction operation. Ann Thorac Surg. 63:1997;1790-1792.
63. Salerno C.T., Harrison B., Hertz M., Shumway S. Coronary artery bypass after single lung transplant a case report . Clin Transpl. 11:1997;463-465.
64. La Francesca S., Shennib H. Coronary artery revascularization followed by single lung transplantation in a patient with combined end-stage idiopathic pulmonary fibrosis and left main coronary artery stenosis. Tex Heart Inst J. 22:1995;189-191.
65. Kachel R.G. Left ventricular function in chronic obstructive pulmonary disease. Chest. 74:1978;286-290.
66. Gabinski C., Courty G., Besse P., et al. Left ventricular function in chronic obstructive lung disease. Bull Physiopathol Resp. 15:1979;755-772.
67. Fishman A.P. Chronic cor pulmonale. Am Rev Respir Dis. 114:1976;775-794.
68. Bahler R.C. Does increased work of the right ventricle diminish left ventricular function? (editorial) Chest. 72:1977;551-552.
69. Baum G.L., Schwartz A., Llamas R., Castillo C. Left ventricular function in chronic obstructive lung disease. N Engl J Med. 281:1971;361-364.
70. Matthay R.A., Berger H.J. Cardiovascular function in cor pulmonale. Clin Chest Med. 4:1983;269-295.
71. Edwards C.W. Left ventricular hypertrophy in emphysema. Thorax. 29:1974;75-80.
72. Michelson N. Bilateral ventricular hypertrophy due to chronic pulmonary disease. Dis Chest. 38:1980;435-446.
73. Matthay R.A., Berger H.J., Davies R., et al. Right and left ventricular exercise performance in chronic obstructive pulmonary disease. Radionuclide assessment. Ann Intern Med. 93:1980;234-239.
74. Matthay R.A., Ellis J.H., Steele P.P. Methoxamine-induced increase in afterload effect on left ventricular performance in chronic obstructive pulmonary disease . Am Rev Respir Dis. 117:1978;871-877.
75. Guidelines for the evaluation and management of heart failure. J Am Coll Cardiol. 26:1995;1376-1398.
76. Krane N.K., Wallin J.D. Managing the elderly patient with both hypertension and pulmonary disease. Geriatrics. 42:1987;45-49.
77. Frauman A.G. An overview of the adverse reactions to adrenal corticosteroids. Adverse Drug React Toxicol Rev. 15:1996;203-206.
78. Oehling A.G., Akdis C.A., Schapowal A., et al. Suppression of the immune system by oral glucocorticoid therapy in bronchial asthma. Allergy Eur J Allergy Clin Immunol. 52:1997;144-154.
79. Faragher M.W., Day B.J., Dennett X. Critical care myopathy an electrophysiological and histological study . Muscle Nerve. 19:1996;516-518.
80. Wolkowitz O.M., Reus V.I., Canick J., et al. Glucocorticoid medication, memory, and steroid psychosis in medical illness. Ann N Y Acad Sci. 823:1997;81-96.
81. LaPier T.K. Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention. J Cardiopulmonary Rehabil. 17:1997;76-84.
82. Braith R.W., Welsch M.A., Mills R.M. Jr, et al. Resistance exercise prevents glucocorticoid-induced myopathy in heart transplant recipients. Med Sci Sports Exerc. 30:1998;483-489.
83. Nesbitt L.T. Jr. Minimizing complications from systemic glucocorticosteroid use. Dermatol Clin. 13:1995;925-939.
84. McKendry R.J.R. The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am. 23:1997;939-954.
85. Cooper J.A.D. Jr, White D.A., Matthay R.A. Drug-induced pulmonary disease. Part I: Cytotoxic drugs . Am Rev Respir Dis. 133:1986;321-340.
86. Ginsberg S.J., Comis R.L. The pulmonary toxicity of antineoplastic agents. Semin Oncol. 9:1982;34-51.
87. Cannon G.W. Methotrexate pulmonary toxicity. Rheum Dis Clin North Am. 23:1997;917-937.
88. Malik S.W., Myers J.L., DeRemee R.A., Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med. 154:1996;1851-1856.
89. Sen R.P., Walsh T.E., Fisher W., et al. Pulmonary complications of combination therapy with cyclophosphamide and prednisone. Chest. 99:1991;143.
90. McCune W.J., Vallance D.K., Lynch J.P. III. Immunosuppressive drug therapy. Curr Opin Rheumatol. 6:1994;262-272.
91. McLaughlin V.V., Genthner D.E., Panella M.M., Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 338:1998;273-277.
92. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 334:1996;296-301.
93. Kovacs I.B., Mayou S.C., Kirby J.D. Infusion of a stable prostacyclin analogue, Iloprost, to patients with peripheral vascular disease lack of antiplatelet effect but risk of thromboembolism . Am J Med. 90:1991;41-46.
94. Raffy O., Sleiman C., Mal H., et al. Paradoxical acute brain thromboembolism during prostacyclin (PGI2) acute challenge for primary pulmonary hypertension. Eur Heart J. 17:1996;153-154.
95. Gulko P.S., Mulloy A.L. Glucocorticoid-induced osteoporosis pathogenesis, prevention and treatment . Clin Exp Rheumatol. 14:1996;199-206.
96. Reid I.R. Osteoporosis - emerging consensus. Aust N Z J Med. 27:1997;643-647.
97. Shane E., Silverberg S.J., Donovan D., et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med. 101:1996;262-269.
98. Haworth C.S., Dodd M.E., Verma A., et al. The prevalence of osteoporosis in adults with cystic fibrosis. Thorax. 52:1997;A44.
99. Bhudhikanok G.S., Lim J., Marcus R., et al. Correlates of osteopenia in patients with cystic fibrosis. Pediatrics. 97:1996;103-111.
100. Aris R.M., Renner J.B., Winders A.D., et al. Increased rate of fractures and severe kyphosis sequelae of living into adulthood with cystic fibrosis . Ann Intern Med. 128:1998;186-193.
101. Grey A.B., Ames R.W., Matthews R.B., Reid I.R. Bone mineral density and body composition in adult patients with cystic fibrosis. Thorax. 48:1993;589-593.
102. Henderson R.C., Madsen C.D. Bone density in children and adolescents with cystic fibrosis. J Pediatr. 128:1996;28-34.
103. Gibbens D.T., Gilsanz V., Boechat M.I., et al. Osteoporosis in cystic fibrosis. J Pediatr. 113:1988;295-300.
104. Mischler E.H., Chesney P.J., Chesney R.W., Mazess R.B. Demineralization in cystic fibrosis. Am J Dis Child. 133:1979;632-635.
105. Bachrach L.K., Loutit C.W., Moss R.B., Marcus R. Osteoporosis in adults with cystic fibrosis. Am J Med. 96:1994;27-34.
106. Stead R.J., Houlder S., Agnew J., et al. Vitamin D and parathyroid hormone and bone demineralization in adults with cystic fibrosis. Thorax. 43:1988;190-194.
107. Haworth C.S., Selby P.L., Webb A.K., Adams J.E. Osteoporosis in adults with cystic fibrosis. J R Soc Med. 91:1998;14-18.
108. Patel S. Current and potential future drug treatments for osteoporosis. Ann Rheum Dis. 55:1996;700-714.
109. Brunelli M.P., Einhorn T.A. Medical management of osteoporosis. Fracture prevention. Clinical Orthop. 348:1998;15-21.
110. McClung M.R. New developments in osteoporosis. Compr Ther. 23:1997;798-803.
111. Karpf D.B., Shapiro D.R., Seeman E., et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate osteoporosis treatment study groups. JAMA. 277:1997;1159-1164.
112. Roux C., Oriente P., Laan R., et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab. 83:1998;1128-1133.
113. Boutsen Y., Jamart J., Esselinckx W., et al. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate a randomized trial . Calcif Tissue Int. 61:1997;266-271.
114. Chadwick J., Mann W.N. The medical works of Hippocrates. 1950;140 Blackwell, Oxford.
115. Lamont C.T., Sampson S., Mathias R., Kane R. The outcome of hospitalization for acute illness in the elderly. J Am Geriatr Soc. 31:1983;282-288.
116. McVey L., Becker P.M., Saltz C.C., et al. Effects of a geriatric consult team on functional status in elderly hospitalized patients. Ann Intern Med. 110:1989;78-84.
117. Hirsch C.H., Sommers L., Olsen A., et al. The natural history of functional morbidity in hospitalized older patients. J Am Geriatr Soc. 38:1990;1296-1303.
118. Convertino V.A., Bloomfield S.A., Greenleaf J.E. An overview of the issues physiological effects of bed rest and restricted physical activity . Med Sci Sports Exerc. 29:1997;187-190.
119. Stremel R.W., Convertino V.A., Bernauer E.M., Greenleaf J.E. Cardiorespiratory deconditioning with static and dynamic leg exercise during bed rest. J Appl Physiol. 41:1976;905-909.
120. Hung J., Goldwater D., Convertino V.A., et al. Mechanisms for decreased exercise capacity after bed rest in normal middle-aged men. Am J Cardiol. 51:1982;343-348.
121. Taylor L.H., Henschel A., Brozek J., Keys A. Effects of bed rest on cardiovascular function and work performance. J Appl Physiol. 2:1949;223-239.
122. Booth F.W. Physiologic and biochemical effects of immobilization on muscle. Clin Orthop. 219:1987;15-20.
123. Rose S.J., Rothstein J.M. Muscle mutability Part 1. General concepts and adaptations to altered patterns of use . Phys Ther. 62:1982;1773-1787.
124. Muller E.A. Influence of training and of inactivity on muscle strength. Arch Phys Med Rehabil. 51:1970;449-462.
125. Shahar A., Powers K.A., Black J.S. The risk of post-operative deconditioning in older adults. (letter) J Am Geriatr Soc. 44:1996;471.
126. Harper C.M., Lyles Y.M. Physiology and complication of bed rest. J Am Geriatr Soc. 36:1988;1047-1054.
127. Becker P.M., McVey L.J., Saltz C.C., et al. Hospital-acquired complications in a randomized controlled trial of a geriatric consultation team. JAMA. 257:1987;2313-2317.
128. Donahoe M., Rogers R.M., Wilson D.O., et al. Oxygen consumption of the respiratory muscles in normal and in malnourished patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 140:1989;385-391.
129. Muers M.F., Green J.H. Weight loss in chronic obstructive pulmonary disease. Eur Respir J. 6:1993;729-734.
130. Wilson D.O., Rogers R.M., Wright E.C., Anthonisen N.R. Body weight in chronic obstructive pulmonary disease the National Institutes of Health intermittent positive pressure breathing trial . Am Rev Respir Dis. 139:1989;1435-1438.
131. Schols A.M.W.J., Slangen J., Volovics L., Wouters E.F.M. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 157:1998;1791-1797.
132. Ferguson G.T., Cherniak R.M. Management of chronic obstructive pulmonary disease. N Engl J Med. 328:1993;1017-1022.
133. Openbrier D.R., Irwin M.M., Rogers R.M., et al. Nutritional status and lung function in patients with emphysema and chronic bronchitis. Chest. 83:1983;17-22.
134. Rochester D.F., Esau S.A. Malnutrition and the respiratory system. Chest. 85:1984;411-415.
135. Kelly S.M., Rosa A., Field S., et al. Inspiratory muscle strength and body composition in patients receiving total parenteral nutrition therapy. Am Rev Respir Dis. 130:1984;33-37.
136. Efthimiou J., Fleming J., Gomes C., et al. The effect of supplementary oral nutrition in poorly nourished patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 137:1988;1075-1082.
137. Wilson D.O., Rogers R.M., Sanders M.H., et al. Nutritional intervention in malnourished patients with emphysema. Am Rev Respir Dis. 134:1986;672-677.
138. Brown S.E., Nagendran R.C., McHugh J.W., et al. Effects of a large carbohydrate load on walking performance in chronic air-flow obstruction. Am Rev Respir Dis. 132:1985;960-962.
139. Burdet L., de Muralt B., Schutz Y., et al. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease a prospective, randomized, controlled study . Am J Respir Crit Care Med. 156:1997;1800-1806.
140. Ferreira I.M., Verreschi I.T., Nery L.E., et al. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest. 114:1998;19-28.
141. Hausler M., Meilicke R., Biesterfeld S., Heimann G. First adult patient with fibrosing colonopathy. Am J Gastroenterol. 93:1998;1171-1172.
142. Kapadia C. Fibrosing colonopathy in cystic fibrosis results of a case-controlled study . Gastroenterology. 111:1996;260-261.
143. Pawel B.R., de Chadarevian J.P., Franco M.E. The pathology of fibrosing colonopathy of cystic fibrosis a study of 12 cases and review of the literature . Hum Pathol. 28:1997;395-399.
144. MacSweeney E.J., Oades P.J., Buchdahl R., et al. Relation of thickening of colon wall to pancreatic-enzyme treatment in cystic fibrosis. Lancet. 345:1995;752-756.
145. Robinson C., Scanlin T.F. Cystic fibrosis. Fishman A.P., Elias J.A., Fishman J.A., Grippi M.A., Kaiser L.R., Senior R.M. Fishman's pulmonary diseases and disorders. 3rd ed. 1998;803-824 McGraw-Hill, New York.
146. Snell G.I., Bennetts K., Bartolo J., et al. Body mass index as a predictor of survival in adults with cystic fibrosis referred for lung transplantation. J Heart Lung Transplant. 17:1998;1097-1103.
147. Kerem E., Reisman J., Corey M., et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 326:1992;1187-1191.
148. Wells K.B., Golding J.M., Burnam M.A. Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry. 145:1988;976-981.
149. Craven J.L., Bright J., Dear C.L. Psychiatric, psychosocial, and rehabilitative aspects of lung transplantation. Clin Chest Med. 11:1990;247-257.
150. Tanoue L.T. Pulmonary toxicity associated with chemotherapeutic agents. Fishman A.P., Elias J.A., Fishman J.A., Grippi M.A., Kaiser L.R., Senior R.M. Fishman's pulmonary diseases and disorders. 3rd ed. 1998;1003-1016 McGraw-Hill, New York.
151. Meier-Sydow J., Weiss S.M., Buhl R., et al. Idiopathic pulmonary fibrosis Current clinical concepts and challenges in management . Semin Respir Crit Care Med. 15:1994;77-96.
152. Hoenig H.M., Rubenstein L.Z. Hospital-associated deconditioning and dysfunction. J Am Geriatr Soc. 39:1991;220-222.